Phase II study of denileukin diftitox (ONTAK) for relapsed/refractory T-cell non-Hodgkin's lymphoma

被引：0
|
作者：
Dang, NH
Pro, B
Fredrick, HR
Samaniego, F
Jones, D
Rodriguez, M
Goy, A
Roaguera, J
Walker, PL
Younes, A
Neelapu, S
Kwak, L
Fayad, L
机构：
[1] Nevada Canc Inst, Las Vegas, NV USA
[2] MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3350
引用
收藏
页码：936A / 936A
页数：1
相关论文
共 50 条
  • [21] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
  • [22] Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
    Ribrag, Vincent
    Caballero, Dolores
    Ferme, Christophe
    Zucca, Emanuele
    Arranz, Reyes
    Briones, Javier
    Gisselbrecht, Christian
    Salles, Gilles
    Gianni, Alessandro M.
    Gomez, Henry
    Kahatt, Carmen
    Corrado, Claudia
    Szyldergemajn, Sergio
    Extremera, Sonia
    de Miguel, Bernardo
    Cullell-Young, Martin
    Cavalli, Franco
    HAEMATOLOGICA, 2013, 98 (03) : 357 - 363
  • [23] Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
    Prince, H. Miles Miles
    Geskin, Larisa J.
    Akilov, Oleg E.
    Kuzel, Timothy M.
    Querfeld, Christiane
    Ooi, Chean Eng
    Xing, Dongyuan
    Sauter, Nicholas
    Singh, Preeti
    Czuczman, Myron
    Foss, Francine M.
    BLOOD, 2022, 140 : 6577 - 6578
  • [24] Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
    Foss, Francine M.
    Kim, Youn H.
    Prince, H. Miles Miles
    Kuzel, Timothy M.
    Yannakou, Costas K.
    Ooi, Chean Eng
    Xing, Dongyuan
    Sauter, Nicholas
    Singh, Preeti
    Czuczman, Myron
    Duvic, Madeleine
    BLOOD, 2022, 140 : 1491 - 1492
  • [25] Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma
    Duvic, Madeleine
    Martin, Ann G.
    Olsen, Elise A.
    Fivenson, David P.
    Prince, H. Miles
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 514 - 519
  • [26] Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    Prince, H. Miles
    Newland, Kate M.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (06): : 625 - 634
  • [27] Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma
    Ansell, Stephen M.
    Tang, Hui
    Nowakowski, Grzegorz S.
    Nikcevich, Daniel
    Nelson, Garth D.
    Erlichman, Charles
    Witzig, Thomas E.
    BLOOD, 2010, 116 (21) : 1178 - 1179
  • [28] Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497
    Kuzel, Timothy M.
    Li, Shuli
    Eklund, John
    Foss, Francine
    Gascoyne, Randy
    Abramson, Neil
    Schwerkoske, John F.
    Weller, Edie
    Horning, Sandra J.
    LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2397 - 2402
  • [29] A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)
    Gribben, JG
    Bartlett, NL
    Stephenson, JJ
    Milder, MS
    Boccia, RV
    Redfern, C
    Mizuno, VM
    Berenson, RJ
    Frohlich, MW
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 76 - 76
  • [30] A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)
    Gribben, JG
    Stephenson, JJ
    Bartlett, NL
    Milder, MS
    Boccia, RV
    Redfern, C
    Mizuno, VM
    Hillson, J
    Berenson, RJ
    Frohlich, MW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 168S - 168S
12345